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Further real growth of transplantation will 
depend on the use of animal organs, an 
elusive goal that depends on first under-
standing how allografts are accepted. For 
nearly 50 years, after Medawar recognised 
that rejection was an immune reaction (1), 
an organ allograft (or xenograft) was 
envisioned as a defenceless island, under 
siege in a hostile recipient sea. 
The mystery of allograft acceptance 
When Billingham, Brent, and Medawar (2, 
3) showed that neonatal tolerance could he 
induced hy engrafting haematolympho-
poietic donor cells into immunologically 
immature mice, the door to transplantation 
was pushed ajar. Simulation of the mouse 
defenceless state with recipient cytoablation 
(4) ultimately allowed clinical BM 
transplantation (5-8) which was long viewed 
as a replacement of the immune system 
(complete donor leucocyte chimerism). 
When histo-incompatible donor BM or 
spleen cells transplanted into mouse (9-11) 
and human recipients (5, 6, 8) rejected the 
immunologically incompetent recipients, it 
appeared to be the same process in reverse 
that destroyed organ allografts. 
The resulting unidirectional paradigm of 
transplantation immunology seemingly 
accommodated the findings following BMT 
but it did not explain organ allograft 
acceptance. In 1962-63, it was found that 
organ rejection, which had previously heen 
considered inexorable in non-cytoablated 
MHC-incompatiblc recipients, could be 
reversed (12). Of equal importance, sub-
sequent immunosuppression requirements 
frequently declined (12). These 2 related 
I-
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events were promptly shown to he generic, 
no matter what the baseline drug or which 
organ (13-15). Their control is the practical 
basis of the clinical field of transplantation. 
This pattern of convalescence (Figure 1) was 
delineated initially from experience with 
kidney transplantation under treatment with 
azathioprine and dose-manoeuverable 
prednisone (12), the first effective double 
drug cocktail. At the time of this first report, 
the donor-specific non-reactivity was 
relative and still drug-dependent. In some 
cases, however, the tolerance became 
complete. A third of a century later, 10 
(22%) of the first 46 Colorado recipients of 
living related donor kidneys (all treated 
before 1964) still have function of their 
original allografts (16). Five of these 10 
kidney recipients are currently drug-free, 
and have been for 3 to 30yr. The cumulative 
time of these pts without drugs equals the 
time on treatment (Figure 2). Two of the 5 
allografts were from HLA identical donors 
(top and third bars). However, 2 were one-
haplotype mismatched (2nd and bottom 
bars), and one patient received a double-
haplotype incompatible kidney from a great 
aun t (second from bottom). Comr lete 
tolerance has also been observed repeatedly 
after HLA mismatched cadaveric liver 
transplantation (17). Amongst our 42 
longest surviving liver recipients, now 15 to 
27yr post-transplantation, 12 (28%) have 
been drug-free for as long as 16yr (16). Their 
cumulative time without immuno-
suppression is almost equal to the time under 
treatment (Figure 3). With more potent 
baseline drugs, survival of all organ grafts 
rose in 3 distinct leaps over a 33yr period 
using azathioprine, cyclosporine, and most 
recently tacrolimus-based immunu-
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Figure 1. Characteristic immunologic confrontation and 
resolution under immunosuppression that is the practical 
basis of organ transplantation 
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Figure 2. Time of immunosuppressive treatment (dark 
shade) and time off drug therapy (light) in 5 non-twin 
living related kidney recipients whose allografts have 
functioned> a third of a century. LO. lit'ing donor 
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Figure 3. Time on (black) and off immunosuppression 
(crosshatched) of 12 (28%) of our 42 longest surviving 
liver recipients (I5-26yr post-transplant) who are 
receiving no treatment as of December, 1995. These drug. 
free pts remain well as of August 1996 . 
• Immu)losutJpression; 0 Nil immunosu(lfJycssion 
suppression (18). However, the sequence 
and timing of immunologic confrontation 
and resolution did not change. It was merely 
better controlled. 
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Disorienation 1962,63 
There was, in fact, no explanation why 
organ allografts would ever survive, much 
less routinely. By 1963, donor leucocyte 
chimerism, the means to the end of 
Medawar's acquired tolerance and the raison 
d' etre of BMT, was eliminated by consensus 
as a factor in organ acceptance. It was the 
beginning of a long trek in the wilderness, 
without a compass, and in the wrong 
direction. 
Passenger leucocytes: The putative enemy 
It was postulated 40yr ago by George Snell 
(19) and confirmed experimentally (20), 
that the highly antigenic passenger leuco-
cytes of BM origin which are a component 
of tissue and organ allografts elicited 
rejection. Consequently, these donor 
leucocytes were viewed by transplanters as 
"the enemy" that had to be destroyed by the 
host immune system if organ transplantation 
was to succeed (Figure 4). This destruction 
could be envisioned at peripheral as well as 
intragraft sites when it was later learned by 
Nemlander and Hayry (21), Larsen et al. 
(22), Demetris and Murase (23), Qian et al 
(24), and others (14-17) that the dClOor 
leucocytes (including dendritic cells) 
promptly migrated in the blood to secondary 
lymphoid sites after organ revascularisation. 
The dichotomy of BM and organ 
transplantation 
The remarkable disparities in treatment and 
outcome, ostensibly involving chimerism for 
Organs: the one way paradigm 
Successful 
- ----. Engraftment 
Figure 4. Conventional view of a successfully 
trumplanted allograft in which the nonparenchymal 
white cells (passenger !eucocytes) were assumed to have 
been destroyed by the host immune system 
D Non parenchymal: B Parenchymal 
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BM but not for organ transplantation, 
sustained the argument for 30yr that these 2 
kinds of procedure were successful hy 
divergent mechanisms. The differences 
(Table 1) were dependence (BM, left 
column) V5. independence on HLA-
matching (organ, right column), risk vs. 
freedom from GVHD, the frequency with 
which the drug-free state could be achieved, 
and a semantic distinction between BM 
tolerance on the one hand and organ graft 
acceptance on the other. As it turned out, 
all of these dissimilarities were more or less 
dependent on a single treatment variable, 
recipient cytoablation for the BM but not 
for the organ recipient. 
An epiphany: 1992 
What had happened after organ trans-
plantation, was recognised in 1992, when 
donor leucocyte chimerism was detected in 
the peripheral tissues or blood of all 30 
human kidney or liver recipients studied 2.5 
to 30yr post-transplantation (14-17, 25). 
Sampling was from blood and multiple 
tissue sites. The sparse chimerism, in which 
dendritic cells were prominent, was 
demonstrated with donor HLA allele 
specific monoclonal antibodies. In addition, 
the presence of Y chromosomes in female 
recipients of male organs was documented 
with in situ hyhridisation (26). Finally, 
donor alleles of chromosome 6 (HLA) 
and/or chromosome 2 (sex) were proven 
with peR. 
The O~way paradigm 
With this information, we postulated that 
clinical organ transplantation under 
immunosuppression involved a douhle 
immune reaction which had host-versus-
graft as we 11 as graft-versus -hos t factors 
(Figure 5). The characteristic cycle of 
immunologic crisis and resolution that is the 
basis of all successful organ transplantations 
was the product of this bi-directional 
modulation. The reciprocal neutralisation of 
the 2 factors explained the blindfolding and 
thus the poor prognostic value of HLA-
matching for organ transplantation (27). 
The cancellation effect also explained the 
rarity of GVHD, even with transplantation 
of lymphoid-rich organs like the liver and 
intestine (14-17, 25, 28). Because the cell-
trafficking is bi-directional, both the 
allograft and recipient become genetic 
composites (Figure 6, upper panel). In 
essence, the passenger leucocytes contained 
in the organ allografts constituted a rapidly 
disseminated fragment of extramedullary 
donor BM (shown as a bone silhouette in 
Figure 6, upper panel) that contains 
pluripotent stem cells (29). 
In the mirror image of successful BMT to 
cytoablated recipients (Figure 6, lower 
panel), a previously unsuspected trace 
population of host leucocytes can invariably 
be found (30, 31). With either organ or 
BMT, veto and suppressor cells, cytokine 
profile changes, and enhancing antibodies 
were viewed as derivative (and accessory) 
phenomena following the primary event of 
Table 1. The dichotomy between BM and organ transplantation 
Critical f- MHC compatibility ~ Not critical 
(jVHD f- Principal complicatiun ~ Rejection 
Commllll f- Drug ti-ce state ~ Rare 
Tolerance f- Term felf success ~ Acceptance 
Yes f- Recipient cytoahlation ~ No 
All differences derive from this therapeutic step 
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mutual cell engagement (Figure 6). 
'TmmlJnOSlIppression 
ReCipIent 
Donor 
Time after transplantation 
Figure 5. Contemporary host- versus-graft (HVG) and 
graft-versus-host (GVH) reactions in the two-way 
paradigm of transplantation immunology. Following the 
initial interaction, the evolution of non-reactivity of each 
leucocyte population to the other is seen as a predominantly low-
grade stimll!iJtory state that may wax and wane, rather than a 
deleticmal one 
Thus, the operational principle of organ 
allograft acceptance by chimerism (Figure 
7) was the same as in the neonatal model 
(2, 3), cytoablation-dependent BMT (2, 3, 
4-8), and "mixed chimerism" tolerance 
models. The last included the parabiosis 
models of Martinez and Cone! (32) and 
those of Slavin and Strober (33), Ildstad 
and Sachs (34), and Judy Thomas (35). 
The theme of chimerism had come full 
circle to the observations by Ray Owen 
51 yr ago of natural tolerance in Freemartin 
cattle (36). 
A 
B 
Unaltered BM 
Two-way paradigm (organ) 
Immunosuppression 
Two-way paradigm (BM) 
GVH 
@) .............. l@® .. @ 
® 
Mutual natural 
Immunosuppression 
~ 
Veto/suppressor cells 
cytokine profile changes 
enhancing antibodies 
HVG 
@) 
Unconditioned 
Not quite defenceles" 
recipient 
Cnoablation 
Ex~raysI drugs) 
, 
Figure 6. Two-way paradigm with which transplantation is seen as a bi-directional and mutually cancelling immune 
reaction that is predominantly HVG with whole organ grafts, and predominantly GVH with BM grafts 
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Freemartin Cattle 
(1945) 
Parabiosis 
(1960) 
Organ Tx 
(1992) 
t 
Billingham/Brent 
Medawar 
(1953) 
t 
Slavin/Strober (1977) 
llstad/Sachs (1984) 
Thomas (1987) 
Figure 7. Continuum of chimerism from observations of Ray Owen in Freemartin cattle to the discovery in 1992 of 
microchimerism in organ recipients 
Transplant success and failure redefined 
Successful transplantation meant that 
chimerism had been introduced which 
might or might not be dependent on 
immunosuppression for stability. Failure 
connoted the therapeutically uncontrollable 
ascendancy of a HVG or GVH reaction. 
The explicit warning contained in this 
definition (14-16) was that quantitation of 
chimerism could not be used to guide drug-
weaning decisions. This conclusion has 
sometimes gone unheeded, not been 
understood, or perhaps simply used as a 
"straw-man" for debating purposes. 
Level vs. duration of chimerism 
There is substantial reason to believe that 
the level of chimerism is less important than 
its duration (15, 16), best illustrated by 
experience with hepatic transplantation. In 
rodent liver-transplant models, the cause 
(chimerism) and effect (tolerance) are 
almost contemporary. In most mouse (24) 
and several rat strain combinations (37, 38), 
tolerance to liver allografts does not even 
require immunosuppression. The same 
observation had been made in the mid-
1960's by Cordier et a1. (39), Peacock and 
Terblanche (40) and CaIne et al (41) in 
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about 15% of outbred pigs (Figure 8). In 
contrast, chimerism and tolerance are 
separated by months or years despite 
immunosuppression in outbred dogs (13), 
and humans (15, 16). In some, the drug-free 
end-point may never be reached, ne-
cessitating a lifetime of immunosuppression 
to maintain hepatic allograft stability. One 
can only assume that the time to reach 
stable chimerism in an animal-to-human 
combination will be off the scale shown in 
Figure 8. 
Adjunct BM infusion 
All transplantation tolerance strategies are 
direct or indirect attempts to alter the 
donor/recipient leucocyte interaction. The 
infusion of unaltered donor BM in organ 
recipients (42, 43), a strategy long-
advocated by Monaco (43, 44), is the most 
primitive example. Our clinical trials with 
adjunct BM for organ recipients (45, 46 and 
further reported in this issue) were hased on 
the premise that persistent chimerism could 
he increased without affecting the rate of 
acute rejection and without increasing the 
risk of GVHD, providing immuno-
suppression was given to both immunocyte 
populations equally (15, 16, 45). These 
- ---------, 
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Time to stable Jonor specific tolerance 
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Figure 8. Time between cause (chimerism) and effect 
(donor specific tolerance) after liver alto-transplantation 
in different species. Note that llnmUlwsuppression is n()t 
universally rc,,{uired in 3 of the 5 s/Jecies shown. 
o Nu immu)l{)sli/Jpression; • ImmltnUsu/J/rression needeLl; 
"OutbreJ 
expectations have been verified in 
approximately 200 cases involving all of the 
major organs including the intestine. 
These were in essence safety questions. The 
therapeutic hypothesis was quite a different 
matter. Here the premises were that the 
threat of delayed acute and chronic 
rejection would be reduced and that the 
frequency of ultimate drug- independence 
would be increased. Full efficacy evaluation 
is expected to take the same 5 to 10yr shown 
in Figure 8, the time frame already 
delineated by 3 decades of human 
experience with MHC incompatible liver 
and BMT (15, 16). 
Procedures that selectively alter one of the 
interacting arms are potentially hazardous, 
exemplified by the historical BMT 
experience with GVHD after unloading the 
host immune system by cytoablation (Figure 
9, lower panel). Delayed multiple EM 
infusions, currently being evaluated in 
Miami (47), could be a more subtle example 
in which the delayed uploading of a partially 
tolerant recipient with infused donor cells 
could have an increased CVHD potential. 
We will depend on the Miami team for 
accurate information about the dimensions 
of the risk of delayed BM infusions in 
human organ recipients. 
Indications have come from rat models in 
which combined BM and liver trans-
plantation done simultaneously under a 
short course of tacrolimus were well tole-
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rated (23). However, when the transplants 
were staged, the second graft (even if it was 
the organ) always caused lethal GVHD 
(Figure 10). The na'ive donor leucocytes 
delivered to the primed rats mimicked the 
outcome of a parent to defenceless offspring 
Fl hybrid model (23). Persico and Remuzzi 
(48) have shown the GVHD potential with 
either simultaneous or staged rat BM and 
kidney allografts (Brown Norway Lewis) 
without any immunosuppression. 
Xenotransplantation 
Xenotransplantation must inevitahly follow 
guidelines imposed by the 2-way paradigm 
(49). The necessity for chi merism was 
recognised a dozen years ago by Ildstad and 
Sachs (34), based on evidence from the rat-
mouse combination. The creation of trans-
genic animals is in essence an attempt to 
improve the cross-species tissue match, 
designed to reduce the acute barrier of 
humoral rejection. This principle, with 
emphasis on the transfection in pigs of 
human complement regulatory genes was 
first postulated by Platt and Bach (50) and 
verified by David White and Jeffrey Platt of 
Cambridge and Duke University, respec-
tively (51-53). 
Such procedures will not, however, resolve 
r 
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Figure 9. ExpLanation of obligatory MHC matching for 
BMT in cytoabLated recipients (second and fourth see-
saws), vs. freedom from this restriction (first and third 
see-saws) if the host immune system is intact 
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Figure 10. Experimental models in rodents revealing the 
risk of qVHD with the delayed migration of naIve 
passenger leucocytes (see text) from subsequently 
transplanted organ. Liver·8M experiments were rel)(JTtcd hy 
Demetris et al. (23). Similar observations with kidnn·bone 
marr()w have been made hy Persico et al. (48) ~ 
the prohlem of maintaining cohabitation of 
the animal and human immune systems for 
the predictably long period required for their 
stable merger (52,53). 
The Zanjani sheep experiments 
A potential crack in the xenotransplant wall 
has been suggested by the experiments of 
Zanjani et al (54, 55), using a modification 
of the Billingham-Brent-Medawar mouse 
model. At the 40 to 50d stage of the 4-5mo 
sheep gestational period, sheep embryos 
were inoculated intraperitoneally with 
leucocytes from human foetal livers, or with 
human stem cells purified from adult BM 
(Figure 11). A handful of the sheep foetuses 
completed their intrauterine life in a healthy 
state and have stable >5% human leucocyte 
chimerism 6 to 7yr later. The chimeric BM 
has been adoptively transferred by inocu-
lation of other sheep foetuses (55). 
Xenogeneic chimerism in pigs 
Is it necessary to go so far back in gestation 
for inoculation, or to use stem cell-rich 
preparations? One year ago, Dr Abdul Rao 
in our laboratory inoculated more than a 
dozen newborn pigs with 5x 1 0') unaltered 
intravenous bahoon (or human) BM cells a 
few hours after birth, with no immuno-
suppression (n=2) or with subsequent 
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tacrolimus only (n=5) or in combination 
with mycophenolate (n=5). The best results 
were without immunosuppression (Tahle 2). 
During the ensuing year, all of the 5 
surviving animals, now weighing 350 to 410 
pounds, have had low level blood (Figure 
12) and/or BM chimerism. 
In related experiments in which unaltered 
human BM was infused into cytoreduced 
adult baboons (750R total lymphoid 
irradiation), human colony forming units of 
all lineages have been grown (18mo post-
transplantation) from the baboon BM (56). 
Our assumption is that interspecies cellular 
tolerance, if it develops at all (particularly in 
the human, neonatal pig model), will 
require protracted mutual exposure of the 2 
cell populations. When the 5 pigs given 
human BM were tested at 11 mo, there was 
evidence of donor-specific hypo-reactivity in 
3 of the 5 animals (Figure 13). This had 
become more pronounced with time (Figure 
14 ). 
However, the critical question is if humoral 
immunity will be abrogated as has been 
reported by Aksentijevich et al.(57)after rat-
mouse xeno-transplantation. In the serum of 
Zanjani's humanised sheep, anti-human 
endothelial antibodies were detectable with 
in vitro assays, even after 2yr of stable 
chimerism (58). 
The decisive test of sheep-human trans-
plantation could not be remotely considered 
without a preliminary parallel study of 
haboonised sheep. This experiment is 
underway in our laboratory after producing 
baboon chimerism in pigs rather than sheep. 
o 
Human leucocyte infusion 
(window from 40-50d) 
40 80 
Sheep gestation in days 
120 
Figure 11. Experiments of Zanjani showing the 
feasibility of inducing neonatal xenogeneic tolerance, by 
the intraperitoneal infusion of human leucocytes into 
sheep foetuses early in their development 
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Table 2. Recipient survival after human to pig BMT 
II 
III 
Ladder 
(+) Control 
(-) Control 
BM + FK + MMF 
BM +FK 
BM+FK 
BM only 
BM only 
2 
5 
5 
Figure 12. Ethidium bromide-stained gel of 
electrophoresed products of double hot start PCR 
amplification of peripheral blood mononuclear ceUs 
(PBMC) obtained from human ---. pig BM recipients at 
340d post-infusion. A primer for DR4 was used for 
detection of human cells; PBMC from untreated animals 
and DR4+ individuals were used as negative and positive 
controls, respectively. Note that human DNA is present 
in all except pig 1 (BM + FK + MMF) blood samples 
tlO --- - -- --
-I 
>< 60 0) 
-a 
9 
SO 40 ~ 
:; 
§ 
c7: 20 
o [ -.1 
BM EM BM+FK BM+FK BM+ 
FK+M!\1F 
Animal treatment 
Figure 13. Mixed lymphocyte reactivity in 5 human --I 
pig BM transplant recipients at approximately 1yr post-
infusion. l'lg PBMC were used as responders against either 
donor or third party splenocytes in a 6d proliferative assay; the 
wells were pulsed with (3 H) thymidine (1 )iCi/well) and 
harvested 12-14h later for the determination of Its incorporatIOn. 
The results are expressed as stimulation index (experimental 
CPM/background CPM). 
D Donor; II Third party 
Human EM 2/2 
2/5 
1/5 
Human BM + FK 506 
Human EM + FK + MMF 
14 
The ultimate pre-clinical test will be pig to 
baboon organ transplantation. 
Adoptive transfer of xenogeneic tolerance 
Such experiments are difficult, expensive, 
and may take years. However, if a level of 
interspecies compatibility is achieved in the 
inoculated pigs, these "golden animals" 
could become a renewable resource that will 
permit colony expansion by transferring the 
pre-adapted BM to supralethally irradiated 
adult pigs or to newborn piglets. The 
eventual clinical objective would be to 
transfer the humanised pig BM to cyto-
ablated pts in preparation for a subsequent 
transplantation of a chimeric organ obtained 
from the expanded colony (Figure 15). 
Transgenic and chimerism technologies 
combined 
Aside from the observations by Rice et al. 
(58), there has been other evidence that 
chimerism alone will not ameliorate the 
hyperacute rejection that follows xenotrans-
plantation between discordant species (49). 
Species restriction of complement activation 
80 - ~~--- ---
>< 60 0) 
-a 
.9 
'" .g 40 
'" :;
§ 
if, 20 
I 
0- J 
75d 349cl 
Post BM infusion 
Figure 14. Donor-specific mixed lymphocyte reactivity in 
a human ---. pig recipient of unmodified BM at 349d as 
compared to that of 75d post-infusion. For methods, refer to 
the legend ot Figure 13. 
D Donor; III Third party 
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Chimeric (golden) pig 
/ Renewable BM 
BM 
/ 
~~ --- BM stage I • 
Cytoablated pigs 
or 
~---
BM stage II 
Untreated newborn pigs 
Cytoablated 
human 
Figure 15. Possible strategy in which humanised (chimeric) pigs are inoculated at birth with unaltered human BM. The 
hypothesis is that the lengthy mutual exposure of the 2 leucocyte populations will lead to tolerance which can be transferred to 
cytoablated or untreated newborn pigs, or ultimately to cytoablated prospective human organ recipients (see text). If this procedure is 
performed on pigs with human complement regulatory genes, the chance of a practical solution to pig -. human xenotransplantation 
shoukl be improved 
has heen descrihed in earlier reports of 
Valdivia et al. (59, 60) and strongly re-
inforced by the recent observations of 
Raj asinghe et a1. (61) in a rat-sheep 
variation of the original Zanjani model. In 
the latter experiments, sheep foetuses 
hyperacutely rejected rat cardiac xenografts 
in the absence of anti-rat antibodies 
(alternative pathway). 
Because the liver is the primary source of 
complement synthesis (62, 63) it will not be 
surprising if the presence of leucocyte 
chimerism fails to reduce the complement 
activation that has been known for more 
than 30yr to he highly targeted to the 
vasculature of whole organ allografts (64-66) 
and xenografts (67, 68). By inducing 
chimerism in pigs who have human 
complement regulatory proteins in their 
organs at birth, the problems of complement 
activation and cellular tolerance can be 
jointly attacked with the strategy shown in 
Figure 15. 
,-- ------
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Summary and conclusions 
The assumption for the last third of a 
century that stem cell-driven haemato-
lymphopoietic chimerism was irrelevant to 
successful conventional whole organ trans-
plantation, has prompted alternative ina-
dequate explanations of organ allograft 
acceptance. This assumption clouded the 
biological meaning of successful organ as 
well as BMT, and precluded the develop-
ment of a cardinal principle that accommo-
dated all facets of transplantation. 
Recognition of this error and the incorpo-
ration of the chimerism factor into a 2-way 
paradigm has allowed previous enigmas of 
organ as well as BM engraftment to he 
explained. No credible evidence has 
emerged to interdict this interactive 
concept. If the 2-way paradigm is correct, it 
will allow the remarkable advances that 
have been made in basic immunology to be 
- - -- --~-
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more meaningfully exploited for trans-
plantation, including that of xenografts. 
Because of the important potential clinical 
implications of Dr. Abdul Rao's experiments 
in which baboon or human bone marrow 
was infused into the neonatal pigs, different 
probes have been used in an attempt to 
validate the presence of chimerism. 
Sustained chimerism in pigs given baboon 
bone marrow was thereby independently 
confirmed. However, Dr. Rao was not able to 
verify the presence in the pigs infused with 
human leukocytes. The reason for the 
discrepancy with the outcome after baboon 
and human infusions is under investigation. 
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